COX-2: a target for colon cancer prevention. Marnett LJ, DuBois RN (2002) Annu Rev Pharmacol Toxicol 42: 55-80 Expression of Activated Ras in Gastric Chief Cells of Mice Leads to the Full Spectrum of Metaplastic Lineage Transitions. Choi E, Hendley AM, Bailey JM, Leach SD, Goldenring JR (2016) Gastroenterology 150: 918-30.e13 Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN (2000) Cancer Res 60: 6045-51 G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD (1996) Cancer Res 56: 733-7 Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compounds. Shimada T, El-Bayoumy K, Upadhyaya P, Sutter TR, Guengerich FP, Yamazaki H (1997) Cancer Res 57: 4757-64 NADPH oxidase activity is essential for Keap1/Nrf2-mediated induction of GCLC in response to 2-indol-3-yl-methylenequinuclidin-3-ols. Sekhar KR, Crooks PA, Sonar VN, Friedman DB, Chan JY, Meredith MJ, Starnes JH, Kelton KR, Summar SR, Sasi S, Freeman ML (2003) Cancer Res 63: 5636-45 The role of cyclooxygenases in inflammation, cancer, and development. Williams CS, Mann M, DuBois RN (1999) Oncogene 18: 7908-16 Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB, deFazio A, Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Goodman MT, Modugno F, Ness RB, Edwards RP, Jensen A, Kjær SK, Høgdall E, Berchuck A, Cramer DW, Terry KL, Poole EM, Bandera EV, Paddock LE, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Pike MC, Webb PM (2017) Br J Cancer 116: 1223-1228 Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma. Sepmeyer JA, Greer JP, Koyama T, Zic JA (2007) J Am Acad Dermatol 56: 584-7 Thiolytic chemistry of alternative precursors to the major metabolite of the cancer chemopreventive oltipraz. Navamal M, McGrath C, Stewart J, Blans P, Villamena F, Zweier J, Fishbein JC (2002) J Org Chem 67: 9406-13 Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. Fowke JH, Longcope C, Hebert JR (2000) Cancer Epidemiol Biomarkers Prev 9: 773-9 Urinary excretion of isoflavonoids and the risk of breast cancer. Zheng W, Dai Q, Custer LJ, Shu XO, Wen WQ, Jin F, Franke AA (1999) Cancer Epidemiol Biomarkers Prev 8: 35-40 Diallyl disulfide causes caspase-dependent apoptosis in human cancer cells through a Bax-triggered mitochondrial pathway. Nagaraj NS, Anilakumar KR, Singh OV (2010) J Nutr Biochem 21: 405-12 A physiological pharmacokinetic model describing the disposition of lycopene in healthy men. Diwadkar-Navsariwala V, Novotny JA, Gustin DM, Sosman JA, Rodvold KA, Crowell JA, Stacewicz-Sapuntzakis M, Bowen PE (2003) J Lipid Res 44: 1927-39 Novel strategies for the early detection and prevention of lung cancer. Wardwell NR, Massion PP (2005) Semin Oncol 32: 259-68 Some dietary and adipose tissue carotenoids are associated with the risk of nonfatal acute myocardial infarction in Costa Rica. Kabagambe EK, Furtado J, Baylin A, Campos H (2005) J Nutr 135: 1763-9 Use of heterologously-expressed cytochrome P450 and glutathione transferase enzymes in toxicity assays. Guengerich FP, Wheeler JB, Chun YJ, Kim D, Shimada T, Aryal P, Oda Y, Gillam EM (2002) Toxicology 181-182: 261-4 Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. Langouët S, Furge LL, Kerriguy N, Nakamura K, Guillouzo A, Guengerich FP (2000) Chem Res Toxicol 13: 245-52 Evolving concepts in lung carcinogenesis. Gomperts BN, Spira A, Massion PP, Walser TC, Wistuba II, Minna JD, Dubinett SM (2011) Semin Respir Crit Care Med 32: 32-43 Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Clark PE, Hall MC, Borden LS, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R, Lovato J, Harmon M, Torti FM (2006) Urology 67: 1257-61
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.